Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTE Trial in Limited-metastatic Gastric or Gastroesophageal Adenocarcinoma
NCT06468280Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of PD-1 Monoclonal Antibody in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Zhongshan Hospital, Fudan University. Started Nov 2024; status: recruiting.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06468280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468280.